Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Robert J. Fram"'
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 3, Pp n/a-n/a (2024)
Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%–12% of all EGFR‐mutated non‐small cell lung cancer (NSCLC) cases. First‐, second‐, and third‐generation tyrosine kinase inhibitors (TKIs)
Externí odkaz:
https://doaj.org/article/8a1983f40da6477da0059eac19192780
Autor:
Joshua F. Zeidner, Flora Mazerolle, Jonathan Norton, Antoine Regnault, Fjoralba Kristo, Heather Romero, Robert J. Fram, Douglas V. Faller, Mehul Dalal, Lionel Ades, Mikkael A. Sekeres
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/95f7a88397bf4e219d56b908c3cff6b5
Autor:
Antoine Regnault, Farrah Pompilus, Anna Ciesluk, Flora Mazerolle, Rafael Bejar, Robert J. Fram, Douglas V. Faller, Patrick Marquis, Jill A. Bell
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 5, Iss 1, Pp 1-10 (2021)
Abstract Purpose Physical functioning and fatigue are key patient concerns in myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). The objective of this research was to generate supportive quantit
Externí odkaz:
https://doaj.org/article/de5ba6e0bd2d46d3a9a051325a0af47b
Autor:
Jill A. Bell, Aaron Galaznik, Farrah Pompilus, Sara Strzok, Rafael Bejar, Fatima Scipione, Robert J. Fram, Douglas V. Faller, Stefan Cano, Patrick Marquis
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-12 (2019)
Abstract Background Novel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leu
Externí odkaz:
https://doaj.org/article/5c00d5c9314c4874932bf05918b400b6
Autor:
Lionel Adès, Larisa Girshova, Vadim A. Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas V. Faller, Mikkael A. Sekeres
Publikováno v:
Scientia
Pevonedistat; Chronic myelomonocytic leukemia Pevonedistat; Leucemia mielomonocítica crónica Pevonedistat; Leucèmia mielomonocítica crònica PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monoth
Autor:
Douglas V. Faller, Justin M. Watts, Atanas Radinoff, Jill A Bell, Lionel Ades, Dan Zhao, Maria Diez Campelo, Nikolay Tzvetkov, Montserrat Arnan Sangerman, Robert J. Fram, Sharon Friedlander, Dominik Selleslag, Joshua F. Zeidner, Jane L. Liesveld, Patricia Font Lopez, Carlos Graux, Marco Cerrano, Mikkael A. Sekeres
Publikováno v:
Leukemia
Leukemia, Vol. 35, no. 7, p. 2119-2124 (2021)
Leukemia, Vol. 35, no. 7, p. 2119-2124 (2021)
TO THE EDITOR : There is a critical unmet need for novel treatments for higher-risk myelodysplastic syndromes (MDS), higher-risk chronic myelomonocytic leukemia (CMML), and low-blast (LB) acute myeloid leukemia (AML). For patients ineligible for stem
Autor:
Patrick Marquis, Aaron Galaznik, Jill A Bell, Fatima Scipione, Farrah Pompilus, Robert J. Fram, Douglas V. Faller, Sara Strzok, Stefan J. Cano, Rafael Bejar
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-12 (2019)
Journal of patient-reported outcomes, vol 3, iss 1
Journal of Patient-Reported Outcomes
Journal of patient-reported outcomes, vol 3, iss 1
Journal of Patient-Reported Outcomes
BackgroundNovel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML
Autor:
Sanjay Goel, Susanna Varkey Ulahannan, Anthony J. Olszanski, Patricia LoRusso, Rachel E. Sanborn, Sunil Sharma, Leisha A. Emens, Matthew Reilley, Victor Priego, Shuli Li, Bingxia Wang, Lixian Dong, Kris Sachsenmeier, John Gibbs, Robert Gharavi, Alonzo Martinez, Igor Proscurshim, Robert J. Fram, Alejandro Gomez-Pinillos, Drew W. Rasco
Publikováno v:
Journal of Clinical Oncology. 40:2506-2506
2506 Background: SUMOylation is a post-translational modification with a role in limiting type 1 interferon (IFN-1)-dependent immune responses. Subasumstat is a small-molecule inhibitor of SUMOylation with the potential to increase antitumor immunity
Autor:
Atanas Radinoff, Dan Zhao, Robert J. Fram, Sharon Friedlander, Dominik Selleslag, Kevin Galinsky, Maria Diez Campelo, Lionel Ades, Justin M. Watts, Douglas V. Faller, Montserrat Arnan, Nikolai Tzvetkov, Patricia Font Lopez, Joshua F. Zeidner, Carlos Graux, Marco Cerrano, Mikkael A. Sekeres, Jane L. Liesveld
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S347-S348
Introduction: Pevonedistat, an investigational, first-in-class NEDD8-activating enzyme inhibitor, disrupts protein homeostasis, leading to cancer cell death. For patients with higher-risk MDS ineligible for transplant, real-world data reveal median o
Autor:
Lionel Ades, Atanas Radinoff, Justin M. Watts, Montserrat Arnan Sangerman, Robert J. Fram, Dan Zhao, Maria Diez Campelo, Patricia Font Lopez, Douglas V. Faller, Jill A Bell, Joshua F. Zeidner, Nikolay Tzvetkov, Sharon Friedlander, Dominik Selleslag, Carlos Graux, Marco Cerrano, Mikkael A. Sekeres, Jane L. Liesveld
Publikováno v:
Leukemia, Vol. 35, no. 12, p. 3637 (2021)
Correction to: Leukemia 10.1038/s41375-021-01125-4, published online 22 January 2021. In Supplementary Table 2, the n numbers for the response-evaluable patients with higher-risk MDS were swapped for the pevonedistat + azacitidine arm and the azaciti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ffef4c86db63fbd0191fa39d33cc3f2
https://hdl.handle.net/2078.1/254643
https://hdl.handle.net/2078.1/254643